Loading
Mauna KEA Technologies Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 20 Nov 2025.
Mauna KEA Technologies: what insiders have been doing
Every trade that managers of Mauna KEA Technologies disclose to AMF is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 1 filing signed by 1 insider.
Every open-market trade in the period is a purchase: 1 purchase worth €100k, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €100k by Alexandre Loiseau, published on 20 November 2025. The buyers include 1 chief executive.
The latest purchase dates back some time: it was published 331 days ago, on 20 November 2025.
For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 1 filing here. Since 2024, the database holds 2 purchases and no sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Insider Decl.
2
Thresholds
n/a
Buy Volume
€109,555
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleAlexandre Loiseau1 buy
Since the insiders bought
- +95.7%Entry €0.07 · Close at T+90 €0.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 2,366 of 24,161 companies
74.0
score / 100
Value70
Quality78
FCF yld-17%
Earn yld47%
EV/EBITDA2.7x
ROE·
Gross mgn75%
Net mgn·
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€0.12
Analyst consensus
Income statement
Revenue€8.2M
Gross profit€6.2M75% margin
EBITDA€12.9M156% margin
Net income€10.8M120.9% margin
Valuation
PER (trailing)1.2x
Beta0.94
Balance sheet & cash
Market cap€22.8M
Total debt€12.1M
Free Cash Flow-€3.9M
Profitability & ownership
ROA-21.9%
% insiders24.4%
% institutions14.5%
Last declaration on 20 November 2025
Declarations2 total
1,027,749 shares@ €0.097391.3% of flowActionEuronext Growth ParisISIN FR00106092632025DD1070501
Canonical exit: 11 Feb 2026 (T+90)
22,222 shares@ €0.438.7% of flowActionEuronext Growth ParisISIN FR00106092632024DD968940
Canonical exit: 1 Sept 2024 (T+90)
2 of 2 declarations
About Mauna KEA Technologies
Mauna Kea Technologies is a French listed medical technology company specialized in in vivo cellular imaging for endoscopy. Founded in 2000 by Sacha Loiseau, a physicist and former NASA Jet Propulsion Laboratory astrophysicist, the company built its identity around Cellvizio®, a proprietary confocal laser endomicroscopy (CLE) platform that enables physicians to visualize cells in real time at very high magnification during endoscopic procedures. The core value proposition is to provide immediate histology-like information at the point of care, helping clinicians improve diagnosis, guide treatment decisions, and make better procedural choices. The company is headquartered in France and operates in a highly international environment, with commercial, regulatory, and clinical activities spanning the United States, Europe, and selected partner markets in Asia.
Mauna Kea Technologies’ business model is centered on the design, commercialization, and ongoing development of the Cellvizio platform, together with its miniature probes and related software. The company serves several medical specialties, notably gastroenterology, pulmonology, urology, and emerging applications in oncology, immunology, and image-guided surgery. Its market position is that of a highly specialized, technology-driven niche player and one of the historical pioneers in endomicroscopy. Management highlights more than 1,100 peer-reviewed publications supporting the technology, along with deployment in hundreds of medical institutions worldwide, which helps underpin the platform’s clinical credibility and scientific recognition.
Read moreShow less
From an industrial strategy standpoint, Mauna Kea Technologies has recently updated its Cellvizio platform and is working to broaden clinical adoption through artificial intelligence, easier workflow integration, and new commercial partnerships. The most recent financial disclosures point to a turnaround phase after a period of revenue pressure and balance-sheet strain. In 2025, the company completed a comprehensive debt restructuring and strengthened equity, while core sales showed a sequential acceleration through the year, supported by the U.S. market and by solutions such as CellTolerance®. In the first quarter of 2026, management reported strong core sales growth and noted additional regulatory momentum, including CE marking under the EU Medical Device Regulation, together with new international expansion opportunities. For investors, Mauna Kea Technologies therefore combines a differentiated medical imaging technology, specialized market exposure, and a still-material financial risk profile, although recent operating trends have become more encouraging in 2026.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
